- Company
- Anti-smoking treatment at public health centers was stopped
- by 박상준 May 20, 2020 06:12am
- From this year, the provision of smoking cessation treatments, such as Champix, through smoking cessation clinics in public health centers will disappear. The MOHW recently removed the provision of anti-smoking treatment Bupropion and Varenicline services from smoking cessation clinics in public health centers by revising the guidelines for t
- Company
- Yuhan, sell anticancer drug 'Glivec' with Novartis
- by Chon, Seung-Hyun May 20, 2020 06:11am
- Yuhan jointly sells anti-cancer drug 'Glivec' with Novartis. While Glivec's patent expired seven years ago, its growth slowed, but it intends to secure stable sales and overcome its recent sluggish earnings. On the 19th, Yuhan announced that it had signed a domestic exclusive sales and joint promotion agreement for Glivec with Novartis. Glive
- Company
- Daewon launches bone forming biosimilar Terrosa
- by Nho, Byung Chul May 20, 2020 06:11am
- On May 18, Daewon Pharmaceutical (CEO Baek Seung Ryel) announced the launch of a biosimilar treating patients with osteoporosis, Terrosa cartridge injection,. Richter-Helm BioTec, a joint venture between a German-based company Helm and a Hungarian-based company Gedeon Richter, has developed biosimilar Terrosa with an active ingredient te
- Company
- Samsung Bioepis' SB11 has equivalence with Lucentis
- by Lee, Seok-Jun May 20, 2020 06:10am
- SB11 (Ranibizumab), Lucentis' Biosimilar by Samsung Bioepis has demonstrated equivalence with the original. This is a global phase III for 705 people. SB11 is Samsung Bioepis' first ophthalmic disease treatment. It is also the sixth antibody biosimilar following three autoimmune disease treatments (SB2, SB4, and SB5) and two tumor disease tre
- Company
- Bispecific antibody by Yuhan & ABL BIO debuts at the AACR 20
- by An, Kyung-Jin May 19, 2020 06:06am
- YH32367/ABL-105, which Yuhan & ABL Bio are jointly developing, debuts on the international stage. Yuhan announced on the 15th that it will announce the results of the preclinical efficacy test of the bispecific antibodies for cancer immunotherapy 'YH32367 (ABL-105)' at the American Association of Cancer Research's 2nd online academic confere
- Company
- Will Hanmi also target Stivarga's patent?
- by Kim, Jin-Gu May 19, 2020 06:06am
- Hanmi's generic launch of Nexavar (Sorafenib) is imminent. Hanmi is considering internally reviewing a plan to target the patent of 'Stivarga (Legorafenib)', a secondary target treatment for liver cancer. If Hanmi succeeds in overcoming patents to Nexavar and Stivarga, it is expected that a lineup of targeted treatments for liver cancer will
- Company
- Pfizer launches Vyndaqel followed by Vyndamax in Korea
- by Eo, Yun-Ho May 18, 2020 06:16am
- Pfizer is expecting to introduce 'Vyndamax' following 'Vyndaqel'. According to the related industry, Pfizer is in the process of approving for Vyndamax (Tafamidis meglumine) by the MFDS, a treatment for cardiomyopathy caused by hereditary transthyretin amyloid polyneuropathy (hATTR-PN) and transthyretin mediated amyloidosis (ATTR-CM). It
- Company
- Hanmi on legal action against Sanofi returning efpeglenatide
- by Chon, Seung-Hyun May 18, 2020 06:14am
- A multinational pharmaceutical company Sanofi has decided to return the rights on antidiabetic candidate medicine efpeglenatide back to Hanmi Pharmaceutical. Apparently, the French-based company is putting an abrupt brake on the development of efpeglenatide, licensed out as the biggest Korean-developed pipeline in 2015. Hanmi Pharmaceutical expl
- Company
- Pharmaceutical industry focuses on Spread of COVID-19 again
- by An, Kyung-Jin May 15, 2020 06:05am
- Pharmaceutical companies are also nervous again as the spread of COVID-19 from Itaewon Club in Seoul. Pharmaceutical companies seem to be cautious about unexpected situations when they tried to earnestly engage in sales marketing activities with the government's distancing in daily life. According to the industry on the 13th, a domestic
- Company
- Sanofi Pasteur GM Baptiste de Clarens to leave Korean office
- by Eo, Yun-Ho May 15, 2020 06:04am
- The General Manager at Sanofi Pasteur Korean office, Baptiste de Clarens is to leave the office at the end of May. According to pharmaceutical industry sources, the resignation of General Manager Baptiste de Clarens has been decided by the headquarter. The decision was apparently made as his term in Korea is ending and a new general manag
